Retail level recall of eight brands of ranitidine products found to contain NDMA

The Health Sciences Authority (HSA) would like to inform healthcare professionals on the retail level recall of eight brands of ranitidine products detected to contain a nitrosamine impurity, N-nitrosodimethylamine (NDMA), that exceeded internationally acceptable level. All locally marketed ranitidine products (with the exception of Gastril Injection) are being recalled. Healthcare professionals are advised to stop prescribing or dispensing the affected ranitidine products and return the remaining stocks to the respective companies. As the potential risks are associated with long term exposure, patients prescribed the affected ranitidine products may continue with their medicines. Please refer to the letter for further details.
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.